Azacitidine every 4 weeks for a course of treatment, generally two courses of treatment to see the effect, if there is no obvious adverse reaction, can increase the dose, the use of Azacitidine should be continued for at least 6 courses of treatment. Azacitidine has anti-tumor effects, clinically used in myelodysplastic syndrome, chronic granulocyte-monocytic leukemia and other diseases treatment. Generally every 4 weeks as a treatment cycle, most patients will take effect after 2 treatment cycles, it is recommended that patients receive at least 6 cycles of treatment. Additional treatment cycles may be added for patients in complete or partial remission. Treatment can be continued as long as the patient continues to benefit. Azacitidine should be used under the supervision of a healthcare professional. The most frequent adverse reactions include nausea, anemia, thrombocytopenia, and vomiting. It is contraindicated in patients with advanced malignant liver tumors and in patients with known hypersensitivity to azacitidine.